- South African courier company DPD Laser has agreed to purchase and distribute Renergen’s (RLT) new vaccine storage cases
- Renergen’s Cryo-Vacc cases allow vaccines to be stored in extremely cold temperatures for 30 days without power supply
- It can also transport a minimum of 100 doses, keeping the vaccine at the required cooling rate
- DPD Laser has agreed to purchase the first 110 cases, which Renergen plans to have ready by the end of May
- The agreement has been finalised ahead of the Phase two vaccination program in South Africa
- Shares last traded in the red, down 4.6 per cent at $2.27
South African courier company DPD Laser has agreed to purchase and distribute Renergen’s (RLT) new vaccine storage cases.
Renergen launched the vaccine storage solution, Cryo-Vacc, to the South African market in February.
In December, the company announced the development of the cases, explaining that it allows vaccines to be stored in extremely cold temperatures for 30 days without power supply.
Further, the cases have been designed to transport a minimum of 100 doses, whilst keeping the vaccine at the required cooling rate of minus 70 degrees Celsius.
Now, DPD Laser, one of South Africa’s leading express courier companies, has agreed to purchase the first 110 Cryo-Vacc cases in a combination of three sizes.
The agreement will see the cases offered to the market on a monthly rental arrangement.
While the agreement is not considered material to Renergen in terms of revenue, it’s still a significant milestone to start manufacturing Cryo-Vacc to customers.
DPD Laser will also provide maintenance, delivery and collection of the cases from maintenance points.
Renergen has started making the cases and expects to deliver all 110 to DPD by the end of next month.
It seems the design is a work in progress, the company said there are still areas of improvement.
Renergen CEO Stefano Marani commented on the development.
“We believe the technology works, and as time progresses, we will continue to enhance and improve the Cryo-Vacc as we gain valuable data from people in the field using the product.”
The agreement comes at an important time as South Africa launches phase two of its COVID-19 vaccination program.
Shares last traded in the red, down 4.6 per cent at $2.27.